Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25281993 | 0.82 | GSK3A (0.43) | GSK3AGSK3BCA1CA9 | |
| SCHEMBL277815 | 0.64 | — | — | |
| SCHEMBL29198019 | 0.64 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL9899911 | 0.62 | GSK3A (0.42) | GSK3AGSK3BCA1CA9 | |
| SCHEMBL9003726 | 0.62 | CA1 (0.44) | GSK3AGSK3BCA1CA9 | |
| SCHEMBL11869157 | 0.62 | CA1 (0.44) | GSK3AGSK3BCA1CA9 | |
| SCHEMBL28494309 | 0.61 | GSK3A (0.40) | GSK3AGSK3B | |
| SCHEMBL21088139 | 0.61 | — | — | |
| SCHEMBL29615515 | 0.60 | — | — | |
| SCHEMBL8858313 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279744-A | Modified thioxanthone photoinitiators | 林特弗德有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-112969965-A | Thioxanthone derivative, composition comprising the same, and pattern forming method comprising the composition | 林特弗德有限公司 | 2021-06-15 | — | — | CN | claimed |
| US-20150196544-A1 | NOVEL BENZO[d][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-20140018390-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| US-8450492-B2 | Deuterated benzo[D][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-1910322-B1 | NOVEL DEUTERATED BENZO [D][1,3]-DIOXOL DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | CONCERT PHARMACEUTICALS INC (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| US-20100222589-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2010-09-02 | — | — | US | disclosed |
| US-7678914-B2 | Deuterated benzo[D][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080287495-A1 | Novel benzo[d][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS INC. | 2008-11-20 | — | — | US | disclosed |
| EP-1910322-A2 | NOVEL BENZO [D][1,3]-DIOXOL DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20080033011-A1 | NOVEL BENZO[D][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20070191432-A1 | Novel benzo[D][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007016431-A2 | NOVEL BENZO [D] [1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033011-A1 | NOVEL BENZO[D][1,3]-DIOXOL DERIVATIVES | TPH1, TPH2, HTR5A | GSK3A 244/4885GSK3B 164/4885CA1 1696/4885 |
| US-20140018390-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, DRD1 | GSK3A 242/4885GSK3B 199/4885CA1 766/4885 |
| US-20100222589-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, DRD1 | GSK3A 242/4885GSK3B 199/4885CA1 766/4885 |
| US-20080287495-A1 | Novel benzo[d][1,3]-dioxol derivatives | TPH1, HTR1D, HTR1A | GSK3A 459/4885GSK3B 394/4885CA1 1342/4885 |
| US-20070191432-A1 | Novel benzo[D][1,3]-dioxol derivatives | TPH1, HTR1D, HTR1A | GSK3A 459/4885GSK3B 394/4885CA1 1342/4885 |
| US-20150196544-A1 | NOVEL BENZO[d][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, HTR1A | GSK3A 459/4885GSK3B 394/4885CA1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.